US Patent

US9062029 — Pyrimidinyl pyridazinone derivatives

Formulation · Assigned to Merck Patent GmbH · Expires 2028-07-04 · 2y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pyrimidinyl pyridazinone derivatives that inhibit tyrosine kinases, particularly Met kinase, for use in treating tumors.

USPTO Abstract

Compounds selected from the group according to Claim 1 are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.

Drugs covered by this patent

tepotinib-hydrochloride (TEPOTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: US9062029
Jurisdiction: US
Classification: Formulation
Expires: 2028-07-04
Drug substance claim: No
Drug product claim: Yes
Assignee: Merck Patent GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.